{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(12)"],"submitter":["Oudard S"],"pubmed_abstract":["<h4>Importance</h4>Many patients 65 years or older with metastatic castration-resistant prostate cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered unsuitable.<h4>Objective</h4>To determine whether biweekly cabazitaxel (CBZ), 16 mg/m2 (biweekly CBZ16), plus prophylactic granulocyte colony-stimulating factor (G-CSF) at each cycle reduces the risk of grade 3 or higher neutropenia and/or neutropenic complications (eg, febrile neutropenia, neutropenic infection, or sepsis) compared with triweekly CBZ, 25 mg/m2 (triweekly CBZ25), plus G-CSF (standard regimen).<h4>Design, setting, and participants</h4>A total of 196 patients 65 years or older with progressive mCRPC were enrolled in this prospective phase 3 randomized clinical trial conducted in France (18 centers)"],"journal":["JAMA oncology"],"pagination":["1629-1638"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10603579"],"repository":["biostudies-literature"],"pubmed_title":["Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial."],"pmcid":["PMC10603579"],"pubmed_authors":["Saldana C","Feyerabend S","Amela E","Voog E","Helissey C","Schostak M","Oudard S","Tran Y","Thiery-Vuillemin A","Belhouari H","Aldabbagh K","Phan L","Pfister D","Sevin E","Di Fiore F","Huillard O","Lange C","Houede N","Bennamoun M","Hasbini A","Besson D","Kotti S","Boegemann M","Von Amsberg G","Quivy A","Ratta R","Barthelemy P"],"additional_accession":[]},"is_claimable":false,"name":"Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial.","description":"<h4>Importance</h4>Many patients 65 years or older with metastatic castration-resistant prostate cancer (mCRPC) are denied taxane chemotherapy because this treatment is considered unsuitable.<h4>Objective</h4>To determine whether biweekly cabazitaxel (CBZ), 16 mg/m2 (biweekly CBZ16), plus prophylactic granulocyte colony-stimulating factor (G-CSF) at each cycle reduces the risk of grade 3 or higher neutropenia and/or neutropenic complications (eg, febrile neutropenia, neutropenic infection, or sepsis) compared with triweekly CBZ, 25 mg/m2 (triweekly CBZ25), plus G-CSF (standard regimen).<h4>Design, setting, and participants</h4>A total of 196 patients 65 years or older with progressive mCRPC were enrolled in this prospective phase 3 randomized clinical trial conducted in France (18 centers)","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-06-01T12:36:28.312Z","creation":"2025-04-19T17:25:55.275Z"},"accession":"S-EPMC10603579","cross_references":{"pubmed":["37883073"],"doi":["10.1001/jamaoncol.2023.4255"]}}